Mark Nuijten

2.0k total citations
72 papers, 1.5k citations indexed

About

Mark Nuijten is a scholar working on Physiology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Nuijten has authored 72 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Physiology, 17 papers in Surgery and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Nuijten's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Nutrition and Health in Aging (12 papers) and Pain Mechanisms and Treatments (8 papers). Mark Nuijten is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Nutrition and Health in Aging (12 papers) and Pain Mechanisms and Treatments (8 papers). Mark Nuijten collaborates with scholars based in Netherlands, Germany and France. Mark Nuijten's co-authors include Karen Freijer, M. Lebmeier, Irene Lenoir‐Wijnkoop, Marc Koopmanschap, John Hutton, B Poulsen Nautrup, Siok Swan Tan, Judith Meijers, Ruud J.G. Halfens and Stefan Walzer and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Urology and British Journal of Cancer.

In The Last Decade

Mark Nuijten

70 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Nuijten Netherlands 22 387 349 280 252 185 72 1.5k
Johan Rosman Australia 30 206 0.5× 372 1.1× 263 0.9× 207 0.8× 86 0.5× 69 2.7k
Frank Bruns Germany 24 167 0.4× 364 1.0× 184 0.7× 86 0.3× 201 1.1× 79 1.9k
Mario Braga Italy 16 211 0.5× 139 0.4× 178 0.6× 148 0.6× 141 0.8× 37 1.3k
Rachel G. Khadaroo Canada 30 506 1.3× 288 0.8× 269 1.0× 130 0.5× 80 0.4× 87 2.5k
Matthew A. Roberts Australia 26 163 0.4× 280 0.8× 153 0.5× 59 0.2× 142 0.8× 79 2.3k
Jason Nelson United States 20 183 0.5× 99 0.3× 162 0.6× 130 0.5× 204 1.1× 56 1.2k
Jamie P. Traynor United Kingdom 22 118 0.3× 287 0.8× 213 0.8× 101 0.4× 45 0.2× 69 2.0k
Ramón Paniagua Mexico 23 202 0.5× 212 0.6× 113 0.4× 194 0.8× 149 0.8× 90 2.2k
Song Vogue Ahn South Korea 25 216 0.6× 184 0.5× 464 1.7× 81 0.3× 84 0.5× 74 1.6k
Valerie Teal United States 27 126 0.3× 281 0.8× 682 2.4× 98 0.4× 186 1.0× 50 2.6k

Countries citing papers authored by Mark Nuijten

Since Specialization
Citations

This map shows the geographic impact of Mark Nuijten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Nuijten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Nuijten more than expected).

Fields of papers citing papers by Mark Nuijten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Nuijten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Nuijten. The network helps show where Mark Nuijten may publish in the future.

Co-authorship network of co-authors of Mark Nuijten

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Nuijten. A scholar is included among the top collaborators of Mark Nuijten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Nuijten. Mark Nuijten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nuijten, Mark, et al.. (2021). A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective. Diabetes Metabolic Syndrome and Obesity. Volume 14. 3147–3160. 4 indexed citations
2.
Freijer, Karen, Irene Lenoir‐Wijnkoop, Colin A. Russell, et al.. (2015). The view of European experts regarding health economics for medical nutrition in disease-related malnutrition. European Journal of Clinical Nutrition. 69(5). 539–545. 12 indexed citations
3.
Bruyère, F., Irene Lenoir‐Wijnkoop, Ivan Tack, et al.. (2015). Infections des voies urinaires : impact économique de la consommation d’eau. Progrès en Urologie. 25(10). 590–597. 2 indexed citations
4.
Lotan, Yair, et al.. (2013). Increased water intake as a prevention strategy for recurrence of urolithiasis: Major impact of compliance on costeffectiveness. Journal of Endourology. 27(2). 129–130. 1 indexed citations
5.
Freijer, Karen, Mark Nuijten, & Jos M. G. A. Schols. (2012). The Budget Impact of Oral Nutritional Supplements for Disease Related Malnutrition in Elderly in the Community Setting. Frontiers in Pharmacology. 3. 78–78. 41 indexed citations
6.
Lotan, Yair, et al.. (2012). Primary prevention of nephrolithiasis is cost‐effective for a national healthcare system. British Journal of Urology. 110(11c). E1060–7. 62 indexed citations
7.
Nuijten, Mark, Javier de Castro, A. Vergnenègre, et al.. (2011). An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Current Medical Research and Opinion. 27(11). 2193–2201. 3 indexed citations
8.
Nuijten, Mark, Javier de Castro, C. Chouaïd, et al.. (2011). A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer. 76(3). 465–471. 15 indexed citations
9.
Nuijten, Mark & Thomas Mittendorf. (2010). A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clinical Therapeutics. 32(4). 717–728. 17 indexed citations
10.
Bischoff, Helge, David F. Heigener, Stefan Walzer, & Mark Nuijten. (2010). Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer. 69. S18–S23. 9 indexed citations
11.
Nuijten, Mark, et al.. (2009). Cost effectiveness of palivizumab in children with congenital heart disease in Germany. Journal of Medical Economics. 12(4). 301–308. 16 indexed citations
12.
Liedgens, Hiltrud, Gabriel Abbam, Mark Nuijten, et al.. (2008). Cost-Effectiveness Analysis of a Lidocaine 5% Medicated Plaster Compared with Gabapentin and Pregabalin for Treating Postherpetic Neuralgia. Clinical Drug Investigation. 28(9). 583–601. 19 indexed citations
13.
Resch, Bernhard, et al.. (2008). Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clinical Therapeutics. 30(4). 749–760. 32 indexed citations
14.
Nuijten, Mark, et al.. (2007). Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children. PharmacoEconomics. 25(1). 55–71. 73 indexed citations
15.
16.
Zanten, Arthur R. H. van, et al.. (2003). Research Importance of nondrug costs of intravenous antibiotic therapy. 1 indexed citations
17.
Palmer, Cynthia S., et al.. (2002). Cost Effectiveness of Treatment of Parkinson??s Disease with Entacapone in the United States. PharmacoEconomics. 20(9). 617–628. 35 indexed citations
18.
Nuijten, Mark. (2001). Assessment of Clinical Guidelines for Continuation Treatment in Major Depression. Value in Health. 4(4). 281–294. 16 indexed citations
19.
Lafuma, A, et al.. (2001). Cost Effectiveness of Emedastine versus Levocabastine in the Treatment of Allergic Conjunctivitis in 7 European Countries. PharmacoEconomics. 19(3). 255–265. 11 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johan Rosman Breakdown of academic impact, for papers by Frank Bruns Breakdown of academic impact, for papers by Mario Braga Breakdown of academic impact, for papers by Rachel G. Khadaroo Breakdown of academic impact, for papers by Matthew A. Roberts Breakdown of academic impact, for papers by Jason Nelson Breakdown of academic impact, for papers by Jamie P. Traynor Breakdown of academic impact, for papers by Ramón Paniagua Breakdown of academic impact, for papers by Song Vogue Ahn Breakdown of academic impact, for papers by Valerie Teal
Rankless by CCL
2026